Development of a novel treatment strategy for renal cell carcinoma using the rare sugar D-allose: Elucidation of the antitumor mechanism.

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09559
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Kagawa University
• Principal Investigator: TAOKA RIKIYA 香川大学, 医学部, 講師 (10403784)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 希少糖 / D-allose / 腎細胞癌

Outline of Final Research Achievements

This research project started with the original hypothesis that rare sugars defined as monosaccharides and their derivatives, which are rarely found in nature, accumulate in renal cell carcinoma, which has high glucose metabolism, and exert anti-tumor effects. Using renal cell carcinoma cells and xenograft mice model, we clarified that the rare sugar D-allose accumulates in renal cell carcinoma cells and tissues and exerts an anti-tumor effect. In addition, based on the results of gene expression profile analysis, proof of the anti-tumor mechanism mediated by the suppressions of Thioredoxin interacting protein and glycolysis has been published and patented as intellectual property, providing fundamental data that will lead to future drug discovery. could be accumulated.

Free Research Field

Cancer biology

Academic Significance and Societal Importance of the Research Achievements

根治切除不能腎細胞癌 は分子標的薬に加え免疫チェックポイント阻害剤が導入され、手術や放射線療法を組み合わせたMulti-Modal Therapyが積極的に行われる現在においても、未だ満足できる治療アウトカムに繋がっていない。一方、食品としての安全性が既に認められている希少糖D-alloseが、世界で初めて高い糖代謝を有する腎細胞癌に蓄積し、その強い抗腫瘍効果と抗腫瘍メカニズムを証明した本研究課題の成果は、極めて高い科学性と社会のニーズに応えるもので、将来で根治切除不能腎細胞癌に対するD-alloseを用いた治療戦略の構築に必須な基盤的データとなる。